Imbruvica
E51059
Bruton tyrosine kinase inhibitor
pharmaceutical drug
small molecule inhibitor
targeted cancer therapy
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
pharmaceutical drug ⓘ small molecule inhibitor ⓘ targeted cancer therapy ⓘ |
| hasAdministrationNote |
should be swallowed whole with water
ⓘ
should be taken at approximately the same time each day ⓘ |
| hasATCCode | L01EL01 ⓘ |
| hasBioavailability | variable and food-dependent ⓘ |
| hasBlackBoxWarningUS |
cardiac arrhythmias
ⓘ
embryo-fetal toxicity ⓘ hemorrhage ⓘ infections ⓘ second primary malignancies ⓘ |
| hasChemicalClass | diaminopyrimidine derivative ⓘ |
| hasCommonAdverseEffect |
bruising
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ rash ⓘ |
| hasDosageForm |
capsule
ⓘ
tablet ⓘ |
| hasEliminationHalfLife | 4 to 6 hours ⓘ |
| hasGenericName | ibrutinib ⓘ |
| hasIndicationRegion |
European Union
ⓘ
United States of America ⓘ
surface form:
United States
|
| hasInitialApprovalYearUS | 2013 ⓘ |
| hasINN | ibrutinib ⓘ |
| hasLegalStatusEU | prescription only ⓘ |
| hasLegalStatusUS | prescription only ⓘ |
| hasMechanismOfAction | irreversible inhibition of Bruton tyrosine kinase ⓘ |
| hasPregnancyCategoryUS | D ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
atrial fibrillation
ⓘ
bleeding ⓘ hypertension ⓘ infections ⓘ |
| isAdministered | once daily ⓘ |
| isContraindicatedWith | strong CYP3A4 inhibitors ⓘ |
| isExcretedVia | feces ⓘ |
| isMarketedBy |
AbbVie
ⓘ
Janssen Biotech ⓘ |
| isMetabolizedBy | CYP3A4 ⓘ |
| isUsedFor |
Waldenstrom macroglobulinemia
ⓘ
chronic graft-versus-host disease ⓘ chronic lymphocytic leukemia ⓘ mantle cell lymphoma ⓘ marginal zone lymphoma ⓘ previously untreated chronic lymphocytic leukemia ⓘ relapsed mantle cell lymphoma ⓘ relapsed or refractory chronic lymphocytic leukemia ⓘ small lymphocytic lymphoma ⓘ |
| targets | Bruton tyrosine kinase ⓘ |
| wasApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.